Zoonotic Visceral Leishmaniasis (ZVL) – A Patient‑Friendly Guide

Overview

Zoonotic visceral leishmaniasis (ZVL), also called kala‑azar, is a severe, systemic disease caused by the protozoan parasites Leishmania infantum (formerly L. chagasi) and, less frequently, L. donovani. The disease is transmitted to humans through the bite of infected female sand‑flies (genus Phlebotomus in the Old World, Lutzomyia in the New World). Unlike the anthroponotic form that spreads directly between humans, ZVL is primarily a **zoonosis** – the parasite circulates among animal reservoirs (mainly dogs, but also wild canids and, occasionally, rodents) and is introduced to humans when sand‑flies feed on an infected animal and subsequently on a person.

Visceral leishmaniasis (VL) attacks the internal organs—primarily the spleen, liver, and bone marrow—leading to profound systemic illness. It is the most lethal form of leishmaniasis if left untreated, with mortality rates up to 10 % even under optimal treatment, and higher in malnourished or immunocompromised patients.

Who it affects: ZVL predominates in the Mediterranean basin (southern Europe, North Africa, the Middle East), parts of Central Asia, and Brazil. Children and young adults are most frequently diagnosed, but any age group can be infected. People living in rural settings, especially those close to kennels, stray‑dog populations, or forested areas where sand‑flies thrive, are at highest risk.

Prevalence: According to the World Health Organization (WHO), an estimated 50 000–90 000 new cases of VL occur worldwide each year, with roughly 60 % attributed to the zoonotic form. In Mediterranean countries, seroprevalence in dogs ranges from 5 % to 30 %, creating a persistent reservoir for human infection.

Symptoms

Symptoms usually appear 2–6 months after the infectious bite, but incubation can be as long as several years. The clinical picture is often non‑specific early on, which can delay diagnosis.

Typical symptom cluster

• Fever – persistent, often low‑grade, worsening at night.
• Weight loss & loss of appetite – progressive wasting despite adequate food intake.
• Splenomegaly – enlarged spleen causing left‑upper‑quadrant fullness or pain.
• Hepatomegaly – enlarged liver, sometimes palpable below the right rib cage.
• Pancytopenia – decreased red cells, white cells, and platelets leading to fatigue, susceptibility to infections, and easy bruising or bleeding.
• Darkening of the skin (hyperpigmentation) – especially on the face and hands, known as “kala‑azar” (black fever).
• Fever‑related “adar” – episodic spikes that may be mistaken for malaria.
• Generalized weakness – often severe enough to limit daily activities.

Less common manifestations

• Focal lesions in the skin or mucosa (rare in ZVL).
• Hepatic dysfunction with mildly elevated transaminases.
• Neurological signs such as confusion or seizures in advanced disease.
• Co‑infection with HIV, which accelerates disease progression and may mask classic signs.

Causes and Risk Factors

Pathogen & Transmission

The causative agent, L. infantum, exists as flagellated promastigotes in the sand‑fly midgut. When the fly bites, promastigotes are inoculated into the human dermis, where they are taken up by macrophages and transform into amastigotes—the intracellular, disease‑causing form. The parasites proliferate within the reticulo‑endothelial system (spleen, liver, bone marrow), evading the immune response.

Key risk factors

• Geographic exposure – residence or travel to endemic regions.
• Proximity to infected dogs – especially stray or unvaccinated canines.
• Living conditions – mud‑brick houses, thatched roofs, and poor sanitation enhance sand‑fly breeding.
• Occupational exposure – farmers, shepherds, veterinarians, and military personnel.
• Age – children <5 years old are more vulnerable due to immature immunity.
• Immunosuppression – HIV infection, chronic steroid use, or chemotherapy.
• Malnutrition – impairs cell‑mediated immunity, a key defense against Leishmania.

Diagnosis

Timely diagnosis hinges on clinical suspicion combined with laboratory confirmation. Because early symptoms mimic malaria, typhoid, or hepatitis, a structured approach is essential.

Laboratory tests

• Serology – rK39 rapid immunochromatographic test (detects anti‑Leishmania antibodies). Sensitivity 90‑95 % in Mediterranean ZVL, specificity ~85 % (Mayo Clinic, 2023).
• Enzyme‑linked immunosorbent assay (ELISA) – quantitative, useful for monitoring treatment response.
• Direct agglutination test (DAT) – high sensitivity, employed in field settings.
• Polymerase chain reaction (PCR) – detects parasitic DNA in blood, bone‑marrow, or tissue; highest specificity, useful for relapse detection.
• Microscopic examination – demonstration of amastigotes in splenic aspirates, bone‑marrow biopsies, or lymph‑node smears. Splenic aspirate yields >95 % sensitivity but carries bleeding risk.

Routine blood work

Complete blood count (CBC) typically shows anemia, leukopenia, and thrombocytopenia. Liver function tests may reveal mild transaminitis; elevated alkaline phosphatase is common due to splenic involvement.

Imaging

• Ultrasound – confirms splenomegaly and may show hypoechoic lesions.
• CT/MRI – reserved for atypical presentations (e.g., hepatic lesions, CNS involvement).

Diagnostic algorithm (simplified)

1. Clinical suspicion based on endemic exposure + compatible symptoms.
2. Perform rapid rK39 test.
3. If positive, confirm with microscopy or PCR.
4. Assess disease severity (CBC, organ size, co‑morbidities) to guide treatment.

Treatment Options

Therapy aims to eradicate the parasite, reverse organ damage, and prevent relapse. Choice of regimen depends on disease severity, patient age, renal/hepatic function, and regional drug availability.

First‑line anti‑leishmanial drugs

• Liposomal amphotericin B (AmBisome®) – 3–5 mg/kg IV daily for 5 days (total 20 mg/kg) or single‑dose 10 mg/kg in some protocols. Preferred due to high cure rates (>95 %) and lower nephrotoxicity (WHO, 2022).
• Miltefosine (Impavido®) – oral 2.5 mg/kg/day for 28 days. Effective (cure ~90 %) but contraindicated in pregnancy and requires monitoring for gastrointestinal side effects.
• Paromomycin (pentavalent aminoglycoside) – 15 mg/kg IM daily for 21 days in combination with miltefosine or amphotericin B in some locales.

Alternative/regimen for drug‑resistant or relapsed disease

• Combination therapy (e.g., amphotericin B + miltefosine) reduces resistance risk.
• Pentavalent antimonials (sodium stibogluconate) – now limited due to toxicity and resistance in many regions.

Supportive measures

• Blood transfusions for severe anemia.
• Platelet or granulocyte transfusions in cases of life‑threatening cytopenias.
• Nutritional rehabilitation – high‑protein, calorie‑dense diet.
• Management of co‑existing infections (e.g., antibiotics for bacterial sepsis).

Follow‑up

Patients should be re‑evaluated at 1, 3, and 6 months post‑treatment with CBC, liver function tests, and serology (rK39 or ELISA) to detect relapse, which occurs in 5‑10 % of cases, especially among immunocompromised hosts.

Living with ZVL (Zoonotic Visceral Leishmaniasis)

Even after successful treatment, many patients experience lingering fatigue, mild splenomegaly, or psychological stress. The following tips can help maintain health and prevent relapse.

Daily management

• Nutrition – Eat iron‑rich foods (lean meat, beans, leafy greens) and vitamin‑C sources to aid iron absorption.
• Hydration – Adequate fluid intake supports kidney function, especially if amphotericin B was used.
• Rest – Allow 7–9 hours of sleep; fatigue can linger for months.
• Monitoring – Keep a symptom diary (fever spikes, bruising, weight change) and share with your clinician.
• Vaccination – Stay up‑to‑date on routine vaccines; avoid live vaccines if immunosuppressed.
• Psychosocial support – Join local or online support groups for leishmaniasis patients; counseling can reduce anxiety.

Interaction with pets

If you own a dog, discuss with a veterinarian the possibility of serological testing and, where available, immunotherapy or treatment with allopurinol to reduce the animal’s infectivity.

Prevention

Because ZVL is a zoonosis, prevention must target both the vector (sand‑flies) and the animal reservoir.

Personal protective measures

• Use insecticide‑treated bed nets (especially for sleeping outdoors or in poorly screened rooms).
• Apply topical repellents containing DEET (20‑30 %) or picaridin at dusk and dawn when sand‑flies are most active.
• Wear long‑sleeved shirts and trousers; treat clothing with permethrin.
• Install fine‑mesh screens on windows and doors; seal cracks in walls.

Environmental control

• Clear organic debris, leaf litter, and animal shelters near homes – these are breeding sites.
• Use indoor residual spraying with pyrethroids in high‑risk villages (WHO recommendation).
• Implement canine vaccination where licensed (e.g., Leish-Tec® in Brazil, CaniLeish® in Europe) and treat seropositive dogs to lower parasite load.

Community‑level strategies

• Regular surveillance of dog populations; culling is discouraged but may be considered in extreme outbreaks under veterinary guidance.
• Health education campaigns emphasizing early symptom recognition and prompt medical evaluation.
• Integrated vector‑management programs coordinated by public health agencies.

Complications

If untreated or inadequately treated, ZVL can lead to life‑threatening sequelae.

• Severe anemia – may cause heart failure.
• Bleeding diathesis – due to thrombocytopenia and coagulopathy.
• Secondary bacterial infections – especially pneumonia and sepsis.
• Hepatosplenomegaly – can progress to portal hypertension.
• Post‑kala‑azar dermal leishmaniasis (PKDL) – skin lesions that appear months after cure, acting as a reservoir for transmission.
• Relapse – more common in HIV‑co‑infected or malnourished patients.
• Death – historically up to 10 % in untreated cases; higher mortality in children and immunocompromised individuals.

When to Seek Emergency Care

---

References (accessed May 2026):

• World Health Organization. Leishmaniasis Fact Sheet. 2022.
• Mayo Clinic. Visceral leishmaniasis (kala‑azar) – Symptoms and causes. 2023.
• Cleveland Clinic. Visceral Leishmaniasis – Diagnosis and Treatment. 2024.
• CDC. Leishmaniasis – Surveillance and Prevention. 2022.
• NIH National Institute of Allergy and Infectious Diseases. Treatment guidelines for leishmaniasis. 2023.
• Alvar J, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE. 2021;16(3):e0248654.
• European Centre for Disease Prevention and Control. Zoonotic visceral leishmaniasis in Europe – Epidemiological update 2024.